Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06372821
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-18
First Post:
2024-03-13
Brief Title:
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Sponsor:
University College London
Organization:
University College London
Study Overview
Official Title:
A Randomized Participant Investigator Blinded Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NIO-SILK
Brief Summary:
This study will assess if drug NIO752 reduces production of a protein tau by the brain Normally tau maintains the internal skeleton of nerve cells In Alzheimers disease AD it builds up in the brain causing damage Abnormal tau proteins cling to each other forming tangles inside nerve cells which interfere with how the nerve cells work and eventually die This is what causes the symptoms of dementia It is thought that NIO752 reduces production of tau
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None